ResearcherRenmin Hospital of Wuhan UniversityNo recent work listed
Ganggang Mu
Matched on OpenAlex author ID A5072227672. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 3
2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper
Papers 3
- Gastrin stimulates pancreatic cancer cell directional migration by activating the Gα12/13-RhoA-ROCK signaling pathway. Co-author DOI 10.1038/s12276-018-0081-6↗
- Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated… Co-author DOI 10.1007/s10620-014-3394-x↗
- Lysophosphatidic acid stimulates activation of focal adhesion kinase and paxillin and promotes cell motility, via LPA1-3, in human pancreatic cancer. First author DOI 10.1007/s10620-013-2878-4↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Honggang Yu · 3 shared papers, 2013–2018 · strength 0.18
- Paper Gastrin stimulates pancreatic cancer cell directional migration by activating the Gα12/13-RhoA-ROCK signaling pathway. DOI 10.1038/s12276-018-0081-6↗
- Paper Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrog… DOI 10.1007/s10620-014-3394-x↗
- Paper Lysophosphatidic acid stimulates activation of focal adhesion kinase and paxillin and promotes cell motility, via LPA1-… DOI 10.1007/s10620-013-2878-4↗
- Yan Liao · 2 shared papers, 2013–2015 · strength 0.11
- Paper Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrog… DOI 10.1007/s10620-014-3394-x↗
- Paper Lysophosphatidic acid stimulates activation of focal adhesion kinase and paxillin and promotes cell motility, via LPA1-… DOI 10.1007/s10620-013-2878-4↗
- Ke He · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.